A61K 40/4285
Lipids
Official title: {Lipids; Lipoproteins}
A61K40/4285 (Lipids) appears on 4 US grants and 23 published applications in this corpus.
Search patents in A61K- Granted patents
- 4
- Published applications
- 23
- Assignees
- 11
- Inventors
- 40
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 2 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 4 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 2 | 3 |
| 2024 | 0 | 3 |
| 2025 | 0 | 5 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric Tim receptors and uses thereof9 Jun 2026US 12,648,964 B2Cero Therapeutics Holdings, Inc.
- Chimeric engulfment receptor molecules23 May 2023US 11,655,282 B2Cero Therapeutics, Inc.
- Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents16 May 2023US 11,649,288 B2Seattle Children's Hospital
- Chimeric antigen receptor specific for SSEA4 antigen30 Apr 2019US 10,273,295 B2Miltenyi Biotec GmbH
- Chimeric tim receptors and uses thereof11 Jun 2026US 2026/0158069 A1Cero Therapeutics Holdings, Inc.
- Novel Treatments for Cardiovascular Related Disease1 Jan 2026US 2026/0000710 A1
- Chimeric tim receptors and uses thereof19 Jun 2025US 2025/0195575 A1Cero Therapeutics Holdings, Inc.
- Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase12 Jun 2025US 2025/0186491 A1
- Compositions for and method of effecting tumor cell death1 May 2025US 2025/0135002 A1Duke University
Most cited
By later US patents